Global Health

how big is Global Health?

As of Jun 06, Global Health Ltd has a market capitalization of 32,298.00 Cr, with recent net sales of 3,692.33 Cr and a net profit of 481.44 Cr for the latest four quarters. Shareholder's funds are 2,428.21 Cr, and total assets amount to 4,090.26 Cr as of Mar'23.

Market Cap: As of Jun 06, Global Health Ltd has a market capitalization of 32,298.00 Cr, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, Global Health reported a sum of Net Sales of 3,692.33 Cr and a sum of Net Profit of 481.44 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'23. Shareholder's Funds are reported at 2,428.21 Cr, while Total Assets amount to 4,090.26 Cr.

Who are in the management team of Global Health?

As of March 2023, the management team of Global Health includes Naresh Kumar Trehan (Chairman & Managing Director), Pankaj Prakash Sahni (Group CEO), and several independent and non-executive directors, ensuring a blend of operational leadership and oversight.

As of March 2023, the management team of Global Health includes the following individuals:<BR><BR>1. Naresh Kumar Trehan - Chairman & Managing Director<BR>2. Pankaj Prakash Sahni - Group CEO & Whole-Time Director<BR>3. Hari S Bhartia - Independent Non-Executive Director<BR>4. Praveen Mahajan - Independent Non-Executive Director<BR>5. Rajan Bharti Mittal - Independent Non-Executive Director<BR>6. Ravi Gupta - Independent Non-Executive Director<BR>7. Ravi Kant Jaipuria - Non-Executive Director / Nominee<BR>8. Sunil Sachdeva - Non-Executive Director<BR>9. Venkatesh Ratnasami - Non-Executive Director / Nominee<BR>10. Vikram Singh Mehta - Independent Non-Executive Director<BR><BR>This team comprises a mix of executive and non-executive directors, with a focus on both operational leadership and independent oversight.

Has Global Health declared dividend?

No Dividend History Available

Who are the peers of the Global Health?

Peers of Global Health include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Aster DM Health, and others. Max Healthcare and Apollo Hospitals show excellent growth and management risk, while Aster DM Health has the highest 1-year return at 78.92%, and Global Health's return is 11.01%.

Peers: The peers of Global Health are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Aster DM Health., Krishna Institu., Rainbow Child., Dr Agarwal's Hea, Jupiter Life Lin, and Health.Global.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Dr Agarwal's Hea, Krishna Institu., Rainbow Child., Jupiter Life Lin, and Global Health, while Average management risk is found at Fortis Health., Aster DM Health., and Health.Global. Growth is excellent at Max Healthcare and Apollo Hospitals, good at Narayana Hrudaya, Dr Agarwal's Hea, and Global Health, while below average growth is seen at Aster DM Health., Krishna Institu., and Rainbow Child. In terms of capital structure, excellent ratings are given to Max Healthcare, Global Health, Krishna Institu., and Jupiter Life Lin, while average ratings are found at Apollo Hospitals and Fortis Health., and below average at Aster DM Health. and Health.Global.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aster DM Health. at 78.92%, while the lowest is Dr Agarwal's Hea with N/A, and Global Health's 1-year return is 11.01%. Additionally, Jupiter Life Lin has a negative six-month return of -3.18%.

What does Global Health do?

Global Health Ltd provides healthcare services in the hospital industry and reported net sales of 9,312 Cr and a net profit of 1,014 Cr for the quarter ending March 2025, with a market cap of INR 35,941 Cr. The company, incorporated in 2004 and transitioned to a public limited company in 2021, has a P/E ratio of 69.00 and a return on equity of 15.34%.

Overview: <BR>Global Health Ltd is engaged in providing healthcare services and operates within the hospital industry as a large-cap company.<BR><BR>History: <BR>Global Health Ltd was incorporated as Global Health Private Limited on August 13, 2004, in New Delhi, India. The company transitioned to a Public Limited Company and changed its name to Global Health Limited on August 11, 2021. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 9,312 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 1,014 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 35,941 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 69.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.12 <BR>Return on Equity: 15.34% <BR>Price to Book: 10.52 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the Global Health?

The top shareholders of Global Health include Naresh Trehan with 33.03%, Dunearn Investments (Mauritius) Pte Ltd at 14.86%, 25 mutual fund schemes holding 10.36%, and 158 Foreign Institutional Investors (FIIs) with a combined 11.76%. Individual investors account for 6.53% of the shareholding.

The top shareholders of Global Health include Naresh Trehan, who is the promoter with the highest holding at 33.03%. The highest public shareholder is Dunearn Investments (Mauritius) Pte Ltd, holding 14.86%. Additionally, the company has 25 mutual fund schemes collectively holding 10.36%, and 158 Foreign Institutional Investors (FIIs) with a combined holding of 11.76%. Individual investors account for 6.53% of the shareholding.

When is the next results date for Global Health?

The next results date for Global Health is 07 November 2025.

The next results date for Global Health is scheduled for 07 November 2025.

Is Global Health overvalued or undervalued?

As of November 19, 2025, Global Health is considered very expensive with a PE ratio of 53.76 and high valuation ratios compared to peers, despite a strong three-year return of 189.89%, indicating it is overvalued in the current market.

As of 19 November 2025, the valuation grade for Global Health has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently deemed overvalued. Key ratios highlight this assessment, with a PE ratio of 53.76, a Price to Book Value of 8.70, and an EV to EBITDA of 33.44, all of which are considerably high compared to industry norms.<BR><BR>In comparison to its peers, Global Health's valuation stands out, particularly when looking at Max Healthcare with a PE of 80.06 and Apollo Hospitals at 64.09. This suggests that while Global Health is indeed very expensive, it is relatively more attractive than some of its peers. Notably, the company has shown a strong return of 189.89% over the past three years, outperforming the Sensex's 38.15% return during the same period, which may contribute to its elevated valuation despite the current market conditions.

How has been the historical performance of Global Health?

Global Health has shown strong financial growth over the past five years, with net sales increasing from INR 1,446.74 crore in March 2021 to INR 3,692.32 crore in March 2025, alongside significant rises in operating profit and profits before and after tax. Despite challenges in cash flow management, the company has expanded its asset base significantly during this period.

Answer:<BR>The historical performance of Global Health shows a consistent upward trend in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Global Health's net sales have increased significantly from INR 1,446.74 crore in March 2021 to INR 3,692.32 crore in March 2025, reflecting a strong growth trajectory. Total operating income followed a similar pattern, rising from INR 1,446.74 crore in March 2021 to INR 3,692.32 crore in March 2025. The company's operating profit (PBDIT) also saw substantial growth, climbing from INR 222.85 crore in March 2021 to INR 956.17 crore in March 2025. Profit before tax increased from INR 32.46 crore in March 2021 to INR 647.26 crore in March 2025, while profit after tax rose from INR 28.81 crore to INR 481.32 crore during the same period. The earnings per share (EPS) showed fluctuations, peaking at INR 60.79 in March 2023 before settling at INR 17.92 in March 2025. On the balance sheet, total assets grew from INR 2,666.29 crore in March 2021 to INR 4,733.21 crore in March 2025, while total liabilities increased from INR 2,668.36 crore to INR 4,733.21 crore. The cash flow from operating activities improved from INR 241 crore in March 2021 to INR 623 crore in March 2025, although the net cash flow showed a decline, ending at INR -194 crore in March 2025 compared to INR -78 crore in March 2021. Overall, Global Health has demonstrated robust growth in revenue and profitability, alongside an expanding asset base, despite some challenges in cash flow management.

Is Global Health technically bullish or bearish?

As of December 4, 2025, the market trend is mildly bearish, with bearish signals from the weekly MACD and Bollinger Bands, despite some mixed bullish indicators, suggesting caution in the current environment.

As of 4 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and Bollinger Bands indicating bearish conditions. The monthly MACD is also mildly bearish, while the daily moving averages show a mildly bullish signal, creating a mixed picture. The KST is bullish on a weekly basis, but the overall trend is influenced by the mildly bearish OBV readings. The Dow Theory reflects a mildly bullish stance on the weekly chart, but with no trend on the monthly. Overall, the bearish indicators outweigh the bullish signals, suggesting caution in the current market environment.

Are Global Health Ltd latest results good or bad?

Global Health Ltd's latest results are concerning, as revenue increased by 18.83% year-on-year, but net profit plummeted by 33.51%, indicating significant operational inefficiencies and margin compression. Overall, the results reflect challenges in maintaining profitability despite revenue growth.

Global Health Ltd's latest results indicate a challenging situation for the company. While the revenue for Q3 FY26 increased by 18.83% year-on-year to ₹1,121.05 crores, the net profit saw a significant decline of 33.51% year-on-year and 40.03% quarter-on-quarter, dropping to ₹95.02 crores. This stark contrast between rising revenues and falling profits highlights serious operational inefficiencies.<BR><BR>The operating margin also contracted sharply to 19.38%, down 582 basis points from the previous year, marking the lowest level in recent quarters. Additionally, the profit after tax margin fell to 8.48%, a decline of 666 basis points year-on-year. These metrics suggest that the company is struggling to convert its revenue growth into profitability, raising concerns about cost management and operational effectiveness.<BR><BR>Investor sentiment appears cautious, reflected in the stock's modest recovery of 1.17% following the results announcement, yet it remains significantly below its 52-week high. Overall, the results are viewed negatively due to the substantial profit decline and margin compression, indicating that Global Health is facing considerable challenges in maintaining profitability despite revenue growth.

Should I buy, sell or hold Global Health Ltd?

Why is Global Health Ltd falling/rising?

As of 05-May, Global Health Ltd's stock price is 1,170.60, down 0.4 points or 0.03%. Despite recent positive performance, concerns about high valuation and low profitability ratios are impacting the stock's current decline.

As of 05-May, Global Health Ltd's stock price is currently at 1,170.60, reflecting a slight decline of 0.4 points or 0.03%. Despite this minor decrease, the stock has shown positive performance over the past week and month, with increases of 3.01% and 16.94%, respectively. However, the year-to-date performance indicates a decline of 1.29%, and the stock has also fallen by 2.45% over the past year.<BR><BR>Several factors contribute to the current stock price dynamics. On the positive side, the company boasts high management efficiency, evidenced by a return on equity (ROE) of 15.69%, and it is net-debt free, which can enhance investor confidence. Additionally, there is significant institutional ownership at 24.91%, suggesting that knowledgeable investors are backing the stock.<BR><BR>Conversely, there are notable concerns that may be influencing the stock's performance. The return on capital employed (ROCE) is at its lowest for the half-year at 17.77%, and the operating profit to interest ratio is also at a low of 10.10 times. Furthermore, the stock is trading at a premium valuation, with a price-to-book value of 8.5, which is higher than its peers' average historical valuations. This premium valuation, combined with a high price-to-earnings growth (PEG) ratio of 4.7, indicates that the stock may be considered expensive relative to its earnings growth.<BR><BR>In summary, while Global Health Ltd has shown strong short-term performance and positive management metrics, concerns regarding its valuation and profitability ratios may be contributing to the current slight decline in its stock price.

Which are the latest news on Global Health?